ATE274357T1 - Texaphyrin-konjugate und ihre anwendiung - Google Patents

Texaphyrin-konjugate und ihre anwendiung

Info

Publication number
ATE274357T1
ATE274357T1 AT99926172T AT99926172T ATE274357T1 AT E274357 T1 ATE274357 T1 AT E274357T1 AT 99926172 T AT99926172 T AT 99926172T AT 99926172 T AT99926172 T AT 99926172T AT E274357 T1 ATE274357 T1 AT E274357T1
Authority
AT
Austria
Prior art keywords
platinum
texaphyrin
conjugates
texaphyrin conjugates
neovascular
Prior art date
Application number
AT99926172T
Other languages
English (en)
Inventor
Jonathan L Sessler
Darren Magda
Tarak Mody
Pavel Anzenbacher
Joan Carvalho
Original Assignee
Univ Texas
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Pharmacyclics Inc filed Critical Univ Texas
Application granted granted Critical
Publication of ATE274357T1 publication Critical patent/ATE274357T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT99926172T 1998-06-05 1999-06-04 Texaphyrin-konjugate und ihre anwendiung ATE274357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8821498P 1998-06-05 1998-06-05
PCT/US1999/012614 WO1999062551A1 (en) 1998-06-05 1999-06-04 Texaphyrin conjugates and uses thereof

Publications (1)

Publication Number Publication Date
ATE274357T1 true ATE274357T1 (de) 2004-09-15

Family

ID=22210058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926172T ATE274357T1 (de) 1998-06-05 1999-06-04 Texaphyrin-konjugate und ihre anwendiung

Country Status (10)

Country Link
US (1) US6207660B1 (de)
EP (1) EP1082138B1 (de)
JP (1) JP2002516878A (de)
KR (1) KR20010052616A (de)
AT (1) ATE274357T1 (de)
AU (1) AU4232199A (de)
CA (1) CA2334809A1 (de)
DE (1) DE69919695T2 (de)
NO (1) NO20006155L (de)
WO (1) WO1999062551A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1698629A3 (de) * 1999-04-30 2006-11-29 Cellgate, Inc. Polyamine und ihre therapeutische Verwendung
EP1223982A2 (de) * 1999-10-29 2002-07-24 Pharmacyclics, Inc. Konjugate zur behandlung von atheroma und andere erkrankungen
JP2004511510A (ja) * 2000-10-16 2004-04-15 ネオファーム、インコーポレイティッド ミトキサントロンのリポソーム製剤
EP1337504A4 (de) * 2000-11-08 2005-10-05 Cellgate Inc Neue polyaminanalogon-aminosäure-konjugate zur verwendung als krebsmittel
US6485704B1 (en) * 2001-05-04 2002-11-26 Mallinckrodt Inc. Azo compound for type I pototherapy
CA2450370A1 (en) * 2001-06-11 2002-12-19 Jody Mesaros Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
US20050261171A1 (en) * 2001-12-13 2005-11-24 Pharmacyclics, Inc. Combination cancer therapy
US20030153493A1 (en) * 2001-12-13 2003-08-14 Pharmacyclics, Inc. Combination cancer therapy
EP1515973A1 (de) * 2002-06-26 2005-03-23 Cellgate Inc. Porphyrin-polyamin-konjugate für die krebstherapie
US20040192665A1 (en) * 2002-08-02 2004-09-30 Slil Biomedical Corporation Conjugates of porphyrin compounds with chemotherapeutic agents
US20090299263A1 (en) * 2002-08-28 2009-12-03 Nomir Medical Technologies, Inc. Near-Infrared electromagnetic modification of cellular steady-state membrane potentials
AU2004232314B2 (en) * 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
NZ546896A (en) 2003-10-07 2010-01-29 Univ Western Sydney Sequence selective pyrrole and imidazole polyamide metallocomplexes
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP1765163A1 (de) * 2004-05-20 2007-03-28 Pharmacyclics, Inc. Verfahren zur verbesserung der visualisierung von atherosklerotischem plaque
DE102005055358A1 (de) * 2005-11-21 2007-05-24 Robert Bosch Gmbh Vorrichtung und Verfahren zum Aufrichten und Übergeben von Faltschachteln
US8133474B2 (en) * 2006-09-15 2012-03-13 Massachusetts Institute Of Technology Sensors for fluorescence and magnetic resonance imaging
KR100800391B1 (ko) 2007-04-06 2008-02-01 김익중 균열방지용 황토미장 시공방법
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
BR112016029024A8 (pt) * 2014-06-11 2021-07-20 Univ Texas composto, composição farmacêutica e uso
WO2022036292A1 (en) 2020-08-14 2022-02-17 Board Of Regents, The University Of Texas System Texaphyrin derivatives for manganese chemotherapy, photoacoustic imaging, and photothermal therapy
CN114539552B (zh) * 2022-03-31 2023-05-02 西安交通大学 一种铂基卟啉金属笼及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5457195A (en) * 1989-12-21 1995-10-10 Board Of Regents, The University Of Texas System Sapphyrin derivatives and conjugates
EP0511275A1 (de) * 1990-01-19 1992-11-04 Nycomed Imaging As Komplexbildner
ES2164043T3 (es) * 1990-05-15 2002-02-16 Hyperion Inc Marcador detectablemente marcado, que comprende un grupo fluoroforo, una sonda fluorescente que comprende el marcador y aplicaciones de los mismos.
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
WO1997019938A1 (es) * 1995-11-29 1997-06-05 Consejo Superior Investigaciones Cientificas Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
GB9710049D0 (en) * 1997-05-19 1997-07-09 Nycomed Imaging As Method
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie

Also Published As

Publication number Publication date
KR20010052616A (ko) 2001-06-25
AU4232199A (en) 1999-12-20
NO20006155L (no) 2001-02-02
DE69919695D1 (de) 2004-09-30
DE69919695T2 (de) 2005-09-15
WO1999062551A1 (en) 1999-12-09
JP2002516878A (ja) 2002-06-11
CA2334809A1 (en) 1999-12-09
EP1082138B1 (de) 2004-08-25
US6207660B1 (en) 2001-03-27
NO20006155D0 (no) 2000-12-04
EP1082138A1 (de) 2001-03-14

Similar Documents

Publication Publication Date Title
DE69919695D1 (de) Texaphyrin-konjugate und ihre anwendiung
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60003583D1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
PT754176E (pt) Novos carbamatos e ureias como modificadores da resistencia a multiplas drogas
DE59611341D1 (de) Verwendung von saccharid-konjugaten
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
BR9813085A (pt) Processo para o tratamento de tumores sólidos em um mamìfero, de doença neoplásica metastática em um mamìfero, de câncer de melanoma, mama, cólon, ovariano, renal, sistema nervoso central, bexiga, próstata ou pulmão em um humano, de doenças neoplásicas em um humano, de distúrbios hematopoiéticos em um mamìfero, composição farmacêutica oral utilizável para o tratamento de doenças neoplásicas em um humano, e, forma de dosagem unitária estéril
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
IL150767A (en) Benzophyrene compounds and their use in the manufacture of drugs for the treatment of estrogen-sensitive diseases such as endometrial cancer
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
EE200000077A (et) Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
BR9912327A (pt) Inibidores da uroquinase
MY136610A (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
BR0010702A (pt) Novas quinonas como terapias de doenças
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
DE69913351D1 (de) Metallkomplexe von chlorinderivaten zum abschirmen von röntgenstrahlen
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082138

Country of ref document: EP

REN Ceased due to non-payment of the annual fee